ARTICLE | Company News
FDA grants Priority Review to pertuzumab
February 8, 2012 1:52 AM UTC
FDA accepted and granted Priority Review to a BLA from Genentech Inc. for pertuzumab as a first-line treatment for HER2-positive metastatic breast cancer. The PDUFA date is June 8. Pertuzumab is a mAb...